NCT02411955 is a Phase 1 clinical trial of Tazarotene Cream 0.1% in Acne Vulgaris, sponsored by Sun Pharmaceutical Industries, Inc..

Who is sponsoring NCT02411955?

NCT02411955 is sponsored by Sun Pharmaceutical Industries, Inc..

What drugs are being tested in NCT02411955?

Interventions in NCT02411955: Tazarotene Cream 0.1%, Tazorac®, Placebo.

What condition does NCT02411955 study?

NCT02411955 studies Acne Vulgaris.

Is NCT02411955 still recruiting?

NCT02411955 is currently completed. Last updated 3 May 2017.

Last reviewed 2017-05-03 · How we verify

NCT02411955

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multiple-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to Tazorac® (Tazarotene Cream 0.1%) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris

Completed Phase 1 Last updated 3 May 2017

What this trial tests

Phase 1 trial testing Tazarotene Cream 0.1% in Acne Vulgaris in 1,077 participants. Completed in 1 February 2015.

Timeline

1 June 2014

Primary endpoint
1 January 2015

1 February 2015

Quick facts

Lead sponsor	Sun Pharmaceutical Industries, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	1,077
Start date	1 June 2014
Primary completion	1 January 2015
Estimated completion	1 February 2015

Drugs / interventions tested

Tazarotene Cream 0.1%
Tazorac®
Placebo

Conditions studied

Acne Vulgaris — all drugs for Acne Vulgaris →

Sponsor

Sun Pharmaceutical Industries, Inc. — full company profile →

Who can join

Adults 12 to 40, any sex, with Acne Vulgaris. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change in inflammatory lesion counts
Time frame: Week 12
Percent change from baseline to week 12 in the inflammatory (papules and pustules) lesion counts
Change in non-inflammatory lesion counts
Time frame: Week 12
Percent change from baseline to week 12 in the non-inflammatory (open and closed comedones) lesion counts

Sponsor's own description

The purpose of this study is to evaluate the therapeutic equivalence and safety of Tazarotene Cream 0.1% and Tazorac® (tazarotene cream 0.1%).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Tazarotene Cream 0.1%

Trials testing the same drug.

NCT03263624 — Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic Nail Disease · Phase 4 · unknown
NCT02886715 — A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatme · Phase 3 · completed

Other recruiting trials for Acne Vulgaris

Currently open trials in the same condition.

NCT07341087 — Skin Inflammation in Perimenopause: A Probiotic Intervention Proof of Concept Trial · NA · recruiting
NCT07474883 — Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris · EARLY_PHASE1 · recruiting
NCT07186413 — A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne · Phase 3 · recruiting
NCT07056673 — Cold Atmospheric Plasma for Moderate-to-severe Acne Vulgaris Study · NA · recruiting
NCT07102186 — Efficacy and Safety of Adapalene Gel and Hyaluronic Acid Versus Adapalene Gel Alone in Mild to Moderate Acne Vulgaris · Phase 4 · recruiting

Other Sun Pharmaceutical Industries, Inc. trials

Trials by the same sponsor.

NCT07469228 — A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne V · Phase 1 · completed
NCT06733402 — A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENC · Phase 1 · completed
NCT06673641 — A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceutica · Phase 1 · completed
NCT06305637 — A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor. · Phase 1 · completed
NCT06673654 — A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02411955 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Pharmaceutical Industries, Inc.
Last refreshed: 3 May 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02411955.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing